Condition: Oropharyngeal Carcinoma · HPV Positive Oropharyngeal Squamous Cell Carcinoma · Sponsor: NYU Langone Health
This is a phase II clinical trial. The purpose of this study is to determine the feasibility of deescalating chemoradiation treatment based on mid-treatment tumor response determined by rapid nodal shrinkage and clearance of circulating HPV plasma tumor DNA . The primary objective of this study is to evaluate progression-free survival at 2 years.
This description comes directly from the study's public registry record.
Kenneth Hu · 212-731-5003 · Kenneth.Hu@nyulangone.org
Fraustina Hsu · cancertrials@nyulangone.org
Always discuss trial participation with your own doctor first.
| New York University School of Medicine | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03215719